Join
Live feed
·
PRReleasevia Quantisnow
TCR2 Therapeutics Inc. logo

TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors

ByQuantisnow·Wall Street's wire, on your screen.
TCRR· TCR2 Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TCRR (TCR2 Therapeutics Inc.) and more on Quantisnow.